Meituan Posts Fourth-Quarter Profit on Travel, Consumption Rebound
By Kimberley Kao
Meituan reported a profit in the fourth quarter on higher revenue, as Chinese consumption continued to recover and local businesses rebounded.
The Beijing-based shopping-and-delivery platform on Friday posted a net profit of 2.22 billion yuan ($308.4 million), compared with a net loss of CNY1.08 billion a year ago. The result exceeded the CNY958.0 million profit expected in a FactSet poll of analysts.
Revenue rose 23% to CNY73.70 billion, marginally beating a FactSet estimate of CNY72.50 billion.
After four straight quarters of profit, 2023 also marked the return to annual profit for one of China's most valuable internet companies.
Meituan reported net profit of CNY13.86 billion on CNY276.74 billion in revenue for the full year.
Write to Kimberley Kao at kimberley.kao@wsj.com
(END) Dow Jones Newswires
March 22, 2024 05:12 ET (09:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track